Cybin Inc. Advances Psychedelic Therapy with Promising Phase 2 Results and Upcoming Trials

LOS ANGELES- Cybin Inc., a clinical-stage biopharmaceutical company at the forefront of psychedelic-based mental health treatments, recently announced encouraging results from its Phase 2 study of CYB003 for Major Depressive Disorder (MDD) and outlined key milestones for its upcoming clinical trials.

The company’s Phase 2 findings revealed a significant breakthrough in treating MDD. The study observed that 79% of patients achieved remission from depression symptoms six weeks after receiving two doses of CYB003 (12mg). These results are especially notable when compared to the efficacy of current standard antidepressants like selective serotonin reuptake inhibitors (SSRIs). CYB003 showed a mean -13.75 point difference in the Montgomery–Asberg Depression Rating Scale (MADRS) score compared to placebo, a statistically significant improvement.

Backed by a robust intellectual property portfolio, including 40 granted patents and over 170 pending applications, Cybin Inc. is preparing to initiate a multinational, multisite Phase 3 trial for CYB003 in early 2024. This step follows the successful completion of a Phase 1/2a study that highlighted CYB003’s potential as an adjunctive therapy in participants with moderate to severe MDD.

In addition to the CYB003 program, Cybin Inc. is advancing its deuterated dimethyltryptamine (dDMT) programs. The company plans to begin a Phase 2 trial of CYB004 in Generalized Anxiety Disorder (GAD) in early 2024. This move comes as the company completes the final analysis of its Phase 1 deuterated DMT readouts (CYB004/SPL028).

Cybin’s commitment to mental healthcare innovation is evident in the breadth of its research and development pipeline. The company has already demonstrated the potential of its dDMT molecules CYB004 and SPL028 in less invasive and more patient-friendly dosing methods. The upcoming milestones for CYB003 and dDMT programs underscore the company’s strategic approach to addressing unmet needs in depression and anxiety disorder treatments.

With a clear focus on revolutionizing mental health therapy, Cybin Inc.’s progress represents a significant step in the field of psychedelic medicine. The company’s upcoming trials and developments are poised to potentially offer new, effective treatment options for individuals struggling with mental health disorders, providing hope for improved outcomes and longer-lasting relief.